CompletedPHASE1, PHASE2NCT02239224
Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATYR1940 in Adult Participants With Muscular Dystrophy
Studying Facioscapulohumeral dystrophy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- aTyr Pharma, Inc.
- Principal Investigator
- Sanjay Shukla, MDaTyr Pharma
- Intervention
- Placebo(biological)
- Enrollment
- 20 enrolled
- Eligibility
- 18-65 years · All sexes
- Timeline
- 2014 – 2015
Study locations (5)
- aTyr Pharma Investigative Site, Rochester, New York, United States
- aTyr Pharma Investigative Site, Columbus, Ohio, United States
- aTyr Pharma Investigative Site, Marseille, France
- aTyr Pharma Investigative Site, Rome, Italy
- aTyr Pharma Investigative Site, Nijmegen, Netherlands
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02239224 on ClinicalTrials.govOther trials for Facioscapulohumeral dystrophy
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07086521Safety and Preliminary Efficacy of ULSC in Facioscapulohumeral Muscular Dystrophy (FSHD)Restem, LLC.
- RECRUITINGPHASE3NCT07038200A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHDAvidity Biosciences, Inc.
- RECRUITINGPHASE1, PHASE2NCT06907875A First-in-human Study of EPI-321 in Facioscapulohumeral Muscular DystrophyEpicrispr Biotechnologies, Inc.
- ENROLLING BY INVITATIONNCT07164937Imaging and Gait Analysis in FSHD PatientsFondazione Policlinico Universitario Agostino Gemelli IRCCS
- RECRUITINGNCT06911190Ten Year Follow-up in FSHD: the FOCUS 3 StudyRadboud University Medical Center
- RECRUITINGNCT07409142BetterLife FSHD: A Patient-driven Health and Research PlatformFSHD Society
- ENROLLING BY INVITATIONPHASE2NCT06547216Phase 2 Open-label Extension Study of AOC 1020 in Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)Avidity Biosciences, Inc.
- RECRUITINGNANCT06600308Walking ANalysis Interest in Persons wiTh facioscapulohumEral Muscular DystrophiesCentre Hospitalier Universitaire Dijon